# US 2025/0025444 A1 · Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0025444 A1
- Document ID: US20250025444A1
- Status: Published application
- Kind: A1
- Application number: 18/900,035
- Filed: 2024-09-27
- Published: 2025-01-23
- Earliest claimed: 2022-05-09
- Assignees: Annovis Bio, Inc.; The Trustees of Columbia University in the City of New York
- Applicants: Annovis Bio, Inc.; The Trustees of Columbia University In the City of New York
- Inventors: Maria Maccecchini; Ottavio Arancio; Erica Acquarone
- Web page: https://patentgrep.com/patent/US20250025444A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G06T 7/80: Analysis of captured images to determine intrinsic or extrinsic camera parameters, i.e. camera calibration
- G06T 2200/24: involving graphical user interfaces [GUIs]
- G06T 2207/30108: Industrial image inspection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL

## Abstract

The invention relates to methods and pharmaceutical compositions effective for treating, inhibiting, preventing, slowing, or delaying the onset of a neurodegenerative disease in mammals (e.g., humans) via the co-administration of an effective amount of a compound selected from the group consisting of Formula (I), Formula (II), Formula (III) or Formula (IV) or pharmaceutically acceptable salts thereof and a phosphodiesterase inhibitor (e.g., a PDE 5 inhibitor). In certain embodiments, the mammal is a healthy human, or a human experiencing cognitive dysfunction with or without hypertension.

## Claims

### Claim 1

A method for treating a neurodegenerative disease comprising co-administration to a human in need thereof:
(1) an amount of a compound selected from the group consisting of Formula (I), Formula (II) and Formula (III):
wherein,
in Formula (I) and Formula (II),
R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
X and Y are, independently, O, S, alkyl, hydrocarbon moiety, C(H)R4, or NR5, wherein R4 and R5 are, independently, hydrogen, oxygen, branched or straight chain C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl; and
R6 is hydrogen; C1-C8 alkyl, C1-C8 alkenyl, C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl, or (CH2)nR7, where R7 is hydroxy, alkoxy, cyano, ester, carboxylic acid, substituted or unsubstituted amino, and n is from 1 to 4;
wherein,
in Formula (III),
R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
X is NR5, wherein R5 is C2-8 alkenyl, C2-8 alkynyl, or aralkyl;
Y is selected from C(H)R4 or NR5, wherein R4 and R5 are, independently, hydrogen, branched or straight chain C1-8 alkyl or heteroalkyl, alkenyl, or C2-C8 alkynyl, aralkyl and wherein the compound having the Formula (I), Formula (II) or Formula (III) is the substantially pure (−)-enantiomer, the substantially pure (+)-enantiomer, or a racemic mixture of the (−)-enantiomer and (+)-enantiomers or a pharmaceutically acceptable salt thereof; and
(2) an amount of a phosphodiesterase inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound selected from the group consisting of Formula (I), Formula (II) and Formula (III) is buntanetap or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the phosphodiesterase inhibitor is 4-[(3-Chloro-4-methoxybenzyl)amino]-8-cyclopropyl-3-(hydroxymethyl) quinoline-6-carbonitrile.

### Claim 4 (depends on 1)

The method of claim 1, wherein the formulation is administered orally, parenterally, intravenously, subcutaneously, sublingually, via suppository, nasally, topically, transdermally, or via an implant under the skin.

### Claim 5 (depends on 4)

The method of claim 4, wherein the human is not demonstrating symptoms of the neurodegenerative disease.

### Claim 6 (depends on 4)

The method of claim 4, wherein the human is demonstrating symptoms of the neurodegenerative disease.

### Claim 7 (depends on 4)

The method of claim 4, wherein the human is not presenting with erectile dysfunction, pulmonary hypertension and benign prostatic hyperplasia.

### Claim 8 (depends on 2)

The method of claim 2, wherein buntanetap or the pharmaceutically acceptable salt thereof is administered (i) orally in an amount from about 1 mg to about 120 mg on a once-a-day basis; (ii) intravenously in an amount from about 0.1 mg to about 25 mg/day; or (ii) intraperitoneally/intramuscularly (IP/IM) in a dose from about 0.3 to about 70 mg/day.

### Claim 9 (depends on 2)

The method of claim 2, wherein buntanetap or a pharmaceutically acceptable salt thereof is administered orally in an amount from about 10 mg to about 80 mg on a once-a-day basis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the administration provides peak plasma circulating levels of buntanetap from about 1 ng/mL to about 380 ng/mL.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compounds are administered in a pharmaceutical formulation together with one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compounds are administered separately but such that they provide overlapping therapeutic effects.

### Claim 13 (depends on 1)

The method of claim 1, wherein the phosphodiesterase inhibitor is a PDE 5 inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the PDE 5 inhibitor is selected from the group consisting of sildenafil, vardenafil, tadalafil, and avanafil, 4-[(3-Chloro-4-methoxybenzyl)amino]-8-cyclopropyl-3-(hydroxymethyl) quinoline-6-carbonitrile, and combinations of any of the foregoing.

### Claim 15

A pharmaceutical composition, comprising
a compound selected from the group consisting of Formula (I), Formula (II) and Formula (III):
wherein,
in Formula (I) and Formula (II),
R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
X and Y are, independently, O, S, alkyl, hydrocarbon moiety, C(H)R4, or NR5, wherein R4 and R5 are, independently, hydrogen, oxygen, branched or straight chain C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl; and
R6 is hydrogen; C1-C8 alkyl, C1-C8 alkenyl, C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl, or (CH2)nR7, where R7 is hydroxy, alkoxy, cyano, ester, carboxylic acid,
substituted or unsubstituted amino, and n is from 1 to 4;
wherein,
in Formula (III),
R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
X is NR5, wherein R5 is C2-8 alkenyl, C2-8 alkynyl, or aralkyl;
Y is selected from C(H)R4 or NR5, wherein R4 and R5 are, independently, hydrogen, branched or straight chain C1-8 alkyl or heteroalkyl, alkenyl, or C2-C8 alkynyl, aralkyl and wherein the compound having the Formula (I), Formula (II) or Formula (III) is the substantially pure (−)-enantiomer, the substantially pure (+)-enantiomer, or a racemic mixture of the (−)-enantiomer and (+)-enantiomers or a pharmaceutically acceptable salt thereof;
a phosphodiesterase inhibitor; and
at least one pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the compound selected from the group consisting of Formula (I), Formula (II) and Formula (III) is buntanetap or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the phosphodiesterase inhibitor is selected from the group consisting of sildenafil, vardenafil, tadalafil, avanafil, 4-[(3-Chloro-4-methoxybenzyl)amino]-8-cyclopropyl-3-(hydroxymethyl) quinoline-6-carbonitrile, and combinations of any of the foregoing.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, which is an oral dosage form.

### Claim 19 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is selected from the group consisting of dementias, tauopathies, chronic traumatic encephalopathy, Parkinson's disease, alpha-synucleopathies, Prion's disease, Down Syndrome, Huntington's disease, Amyloid Lateral Sclerosis, multiple sclerosis, and other dementias and neurodegenerative disorders which present as misfolding, aggregation and accumulation of proteins in the brain.

### Claim 20 (depends on 1)

The method of claim 1, wherein the co-administration provides a synergistic therapeutic effect.
